Alicia Granados | Global Head Scientific Advocacy and Insights
Sanofi

Pre-congress workshops @ 14:00

HTAi: Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Moderator: Sheela Upadhyaya, Rare Disease Consultant, Rarely Ordinary

×

Sheela Upadhyaya / HTAi: Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Sheela Upadhyaya, Rare Disease Consultant,
Rarely Ordinary

Sheela Upadhyaya Founder, Rarely Ordinary | Rare Disease, Health Policy and Life Sciences Expert Sheela Upadhyaya is the founder of Rarely Ordinary and a highly respected rare disease, health policy and life sciences expert. With more than 20 years’ experience across the NHS, NICE, government and ...

CloseMore

Alicia Granados, Global Head Scientific Advocacy and Insights, Sanofi

Veronica Lopez Gousset, DrPH candidate, Harvard T.H. Chan School of Public Health

×

Veronica Lopez Gousset / HTAi: Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Veronica Lopez Gousset, DrPH candidate,
Harvard T.H. Chan School of Public Health

Veronica Lopez Gousset, MPH, has over 10 years of experience ensuring patients’ voices are represented in healthcare decision-making. She works with the patient community to better voice their needs and challenges, with health technology assessment (HTA) bodies to improve their processes for...

CloseMore

Dorota Zgodka, Steering Committee member, HTAi Rare Disease Interest Group

Sanja Fitzgerald, Technical Officer Rare Disease Interest Group, HTAi

×

Sanja Fitzgerald / HTAi: Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Sanja Fitzgerald, Technical Officer Rare Disease Interest Group,
HTAi

Dr Sanja Fitzgerald is a market access and HTA advisor supporting biotechnology and pharmaceutical companies on pricing, access, evidence strategy and EU HTA/JCA. Her work focuses on connecting clinical development and evidence-generation decisions with HTA outcomes, patient access and commercial...

CloseMore

Wija Oortwijn, Senior Lecturer, ZIN & Radboud University Medical Center

×

Wija Oortwijn / HTAi: Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Wija Oortwijn, Senior Lecturer,
ZIN & Radboud University Medical Center

Dr. Wija Oortwijn studied health sciences, holds a PhD in Medicine and has 35 years of relevant professional experience in health technology assessment (HTA) and health policy analysis around the globe. Currently, she is senior lecturer in HTA at Radboud University Medical Center as well as chair...

CloseMore

Eric Low, Director, Eric Low Consulting Ltd

Theodora Weisz, Patient Affairs Expert Advisor, FMF Patient Organisation

Day 2 @ 11:15

Panel: Improving access through innovation of evidence generation and assessment

-       The IHI RealiseD project – Improving evidence generation

-       The HTAi Rare Disease Interest Group – Improving evidence assessment

Moderator: Karen Facey, Senior HTA Advisor, University of Edinburgh

×

Karen Facey / Panel: Improving access through innovation of evidence generation and assessment

Karen Facey, Senior HTA Advisor,
University of Edinburgh

Karen Facey worked as a senior statistician in Pharma and medicines regulation before moving to Scotland in 2000 to setup their first national HTA agency. Since 2003 she has been an independent consultant working with all stakeholders on matters relating to HTA in Europe and Canada, with special...

CloseMore

Alicia Granados, Global Head Scientific Advocacy and Insights, Sanofi

Session led by:

Day 2 @ 11:15

Panel: Improving access through innovation of evidence generation and assessment

-       The IHI RealiseD project – Improving evidence generation

-       The HTAi Rare Disease Interest Group – Improving evidence assessment

Moderator: Karen Facey, Senior HTA Advisor, University of Edinburgh

×

Karen Facey / Panel: Improving access through innovation of evidence generation and assessment

Karen Facey, Senior HTA Advisor,
University of Edinburgh

Karen Facey worked as a senior statistician in Pharma and medicines regulation before moving to Scotland in 2000 to setup their first national HTA agency. Since 2003 she has been an independent consultant working with all stakeholders on matters relating to HTA in Europe and Canada, with special...

CloseMore

Alicia Granados, Global Head Scientific Advocacy and Insights, Sanofi

Session led by: